ASLN | ASLAN Pharmaceuticals Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6000 - 0.6999
52 Week Range	0.4750 - 17.04
Beta	0.58
Implied Volatility	641.46%
IV Rank	96.64%
Day's Volume	769,822
Average Volume	102,493
Shares Outstanding	2,828,350
Market Cap	1,697,010
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-05-04

Valuation
Profitability
Growth
Health
P/E Ratio	-0.04
Forward P/E Ratio	N/A
EPS	-16.00
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	35
Country	Singapore
Website	ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

ASLN's peers: IOBT

*Chart delayed

Analyzing fundamentals for ASLN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ASLN Fundamentals page.

Watching at ASLN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ASLN Technicals page.